苯磺酸左旋氨氯地平与厄贝沙坦联用对高血压伴冠心病患者的临床疗效评价

Evaluation on Clinical Efficacy of Levamlodipine Besylate Combined with Irbesartan in Hypertension Patients with Coronary Artery Disease

目的:评价苯磺酸左旋氨氯地平与厄贝沙坦联用对高血压伴冠心病患者的临床疗效。方法:选取2012年11月—2015年8月间诊治的高血压伴冠心病患者95例,按照随机数字表法将患者分为治疗组(48例)和对照组(47例);治疗组患者均给予苯磺酸左旋氨氯地平片与厄贝沙坦分散片联用治疗,对照组患者均给予厄贝沙坦分散片治疗,比较两组患者治疗后的血压及血脂各指标值、总有效率及不良反应的发生率。结果:治疗后治疗组患者的收缩压、舒张压值明显低于治疗前(P<0.05);对照组患者的收缩压、舒张压值明显低于治疗前(P<0.05),治疗组患者的收缩压、舒张压值明显低于对照组(P<0.05);治疗后治疗组患者的三酰甘油(TG)、总胆固醇(TC)、低密度脂蛋白胆固醇(LDL-C)和高密度脂蛋白胆固醇(HDL-C)值明显低于治疗前(P<0.05);对照组患者的TG、TC、LDL-C和HDL-C值明显低于治疗前(P<0.05);治疗组患者的TG、TC、LDL-C和HDL-C值明显低于对照组(P<0.05);治疗组患者临床治疗总有效率明显高于对照组(P<0.05);两组患者治疗期间不良反应发生率经比较其差异无统计学意义(P>0.05)。结论:苯磺酸左旋氨氯地平与厄贝沙坦联用治疗较单用厄贝沙坦对高血压伴冠心病患者的临床疗效好,其血压及血脂各指标值易控制,且无不良反应症状的发生。

Objective： To evaluate the clinical efficacy of levamlodipine besylate combined with irbesartan in hyper- tension patients with coronary artery disease. Methods： The 95 hypertension patients with coronary artery disease were selected between November 2012 and Auguest 2015. They were divided into experimental group（48 cases） and control group（47 cases） according to random number table.The experimental group patients were given levamlodipine besylate tablets combined with irbesartan dispersible tablets, and control group patients were given irbesartan dispersible tablets. The blood pressure, serum lipid value, clinical total effective rate and adverse effects rate of patients in two group were compared. Results： After treatment the systolic pressure and diastolic blood pressure in experiment group were lower than prior to treatment（P〈0.05）, and the systolic pressure and diastolic blood pressure in control group were lower than those before treatment（P〈0.05）, while the systolic pressure and diastolic blood pressure in experiment group were lower than those control group（P〈0.05）. The TG, TC, LDL-C and HDL-C value of experiment group were lower than those be- fore treatment（P〈0.05）, and the TG, TC, LDL-C and HDLC value of control group were lower than those before treat- ment（P〈 0.05）, while the TG, TC, LDL-C and HDL-C value of experiment group were lower than those of control group （P〈 0.05）. The effective rate of experimental group patients was higher than that of control group （P〈 0.05）, however, the adverse effect rate of patients in two groups had no significant difference（P〉0.05）. Conclusion： Compared with irbesar- tan, levamlodipine besylate combined with irbesartan had achieved good clinical efficacy in the treatment of hypertension patients with coronary artery disease. It had good control over the blood pressure and serum lipid value, and there were no adverse effects rate.